Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Famotidine Injection. This approval marks a significant step for the company in expanding its pharmaceutical offerings and strengthening its position in the market, potentially impacting its stakeholders positively by enhancing its product portfolio.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, primarily involved in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market emphasis on innovative and generic drugs.
YTD Price Performance: 96.84%
Average Trading Volume: 11,114,885
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.96B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.